Does Synchronizing Brain Waves Bring Harmony?
Based on early stage trials, scientists said at AD/PD that light and sound can promote neuronal communication, calm immune cells, and slow brain atrophy. On cognitive outcomes, the jury is still out.
ALL NEWS
5783 RESULTS
Sort By:
- Most Recent
- Most Commented
Advisory Committee Again Urges FDA to Vote No on Aducanumab
After news on “new data” they won’t see, three committee members penned an editorial laying out their argument against approval. The agency is expected to decide on the licensing application by June.
Squelching ApoE in Astrocytes of Tau-Ravaged Mice Dampens Degeneration
In therapy-like paradigm, suppressing ApoE4 in astrocytes toned down tauopathy. This assuaged microglia, neurodegeneration, and revived nest-building.
What BACE Hits: New Substrates Create New Headaches
New research implicates IL-6 signaling and even Aβ42 itself as BACE targets, complicating efforts to resurrect BACE inhibitors at a low dose.
Drop of Hope? No Cognitive Worsening on BACE Inhibitor
Data from Phase 3 trials of elenbecestat show no harm to cognition, leaving open a chance that the drugs could be used safely in the future.
Dysfunctional Lysosomes Cause Ferroptosis in Neurons
The first whole-genome manipulation of protein expression in neurons by CRISPR reveals a deadly chain of events. Bad processing by lysosomes leads to build-up of lipids and iron. Oxidative stress revs up. Neurons die by ferroptosis.
TREM2 Variants and CSF sTREM2 Levels Differ by Race
African Americans are likelier than non-Hispanic Caucasians to carry low-expression TREM2 variants, and less likely to carry a high-expression variant. As a result, they have less soluble TREM2 in their cerebrospinal fluid.
Clinical Trials in COVID Era: How To Keep Moving Forward
By shifting to home nursing and telemedicine, clinical researchers kept inching ahead during lockdowns.
COVID-19 Worsens Neurological Problems, Delirium
At AD/PD 2021, clinicians discussed neurological symptoms and brain tissue damage in older people who died from COVID-19.
For α-Synuclein Immunotherapy, Is Going Later the Key?
In the negative Phase 2 trial of prasinezumab, populations with more rapid decline benefited; this informed the design of a new Phase 2b study.
Field Loses David Allsop, First to Isolate Amyloid
Both shy and funny, Allsop was a pioneer of modern Alzheimer's research.
New Mouse Models Better Mimic Tauopathy, Alzheimer's
Two mouse models presented at AD/PD may hand scientists more translationally relevant tools to explore LOAD pathophysiology and treatment. The tricks: targeted replacement and knocking in multiple GWAS variants.
Clinicians from Developing Nations Discuss Dementia in Their Populations
As life expectancy increases in countries such as Nigeria, Brazil, China, and others, so does the number of people with dementia. How to provide modern care for them?
Where to Now, Phospho-Tau?
Researchers envision p-tau-based blood tests for Alzheimer’s disease within a few years, but maybe not a stand-alone test.
N-Terminal Tau Antibodies Fade, Mid-Domain Ones Push to the Fore
The field is shifting from targeting tau’s tips to its mid-region, especially where tau binds microtubules. Several new candidates are in the clinic; whether the strategy will work remains to be seen.
Current Filters
- Date Range : All x